NJRetina

What NJRetina does

NJRetina (legal entity: Associated Retinal Consultants, L.L.C.) is a private ophthalmology and vitreoretinal surgery practice headquartered in Belleville, New Jersey, and founded in 1995. It operates as the largest single-state network of retina specialists in New Jersey, with 20 office locations spanning Toms River to Wayne and a staff of 33+ board-certified ophthalmologists and vitreoretinal surgeons trained at institutions including Harvard, Columbia, Johns Hopkins, Wills Eye, and UCLA. The practice is an affiliate of PRISM Vision Group, whose CEO/President (Dr. Steven Madreperla) also serves as NJRetina's President.

The practice delivers a comprehensive clinical service line covering the full spectrum of retinal disease: diagnostic retinal examination (fundus photography, fluorescein angiography, OCT, visual field testing); office-based intravitreal injection therapies (anti-VEGF agents — Avastin, Lucentis, Eylea, Beovu — and steroid implants including Ozurdex); laser procedures (photocoagulation, retinopexy, photodynamic therapy); and vitreoretinal surgery (vitrectomy, scleral buckling, pneumatic retinopexy, cryotherapy). It maintains an active multi-center clinical trials program across geographic atrophy, retinitis pigmentosa, and diabetic macular edema, and runs an AUPO-accredited 2-year vitreoretinal fellowship in collaboration with Rutgers Robert Wood Johnson University Hospital.

NJRetina generates revenue through fee-for-service clinical care billed to Medicare, Medicare Advantage, and commercial insurance, augmented by a Continuous Care Program delivered in partnership with Lumata Health. Most patients are acquired via referrals from general ophthalmologists and primary care physicians, with a secondary direct-to-consumer channel via phone (855-NJRETINA) and online appointment booking. Specialty care coordination, imaging records retention, and physician reputation create durable patient retention across longitudinal anti-VEGF treatment courses.

Name

NJRetina

Legal name

Associated Retinal Consultants, L.L.C.

Website

https://njretina.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

NJRetina is a private ophthalmology and vitreoretinal surgery practice operating 20 locations across New Jersey with 33+ board-certified specialists, delivering diagnostic, injection, laser, and surgical care for retinal diseases under Medicare, Medicare Advantage, and commercial insurance.

Ownership category

akta.pro rank

Product category

Ophthalmology / Vitreoretinal Care

NAICS

Offices of Physicians (except Mental Health Specialists) (621111), Offices of Physicians (62111), Offices of Physicians (6211)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAKAKAE

Retina & Vitreous Specialists

Healthcare & Life Sciences/Specialist Medical Practice/Ophthalmology & Optometry

SECONDARYHLAKAKAN

Ocular Imaging & Diagnostic Testing Centers

Healthcare & Life Sciences/Specialist Medical Practice/Ophthalmology & Optometry

SECONDARYHLAKAKAO

Ambulatory Surgery Centers (Ophthalmic/Outpatient Eye Surgery)

Healthcare & Life Sciences/Specialist Medical Practice/Ophthalmology & Optometry

SECONDARYHLAFAIAF

Ophthalmology Surgery Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Surgical Centers & Perioperative Care (ASCs)

Keywords

• Retinal disease treatment
• Vitreoretinal surgery
• Ophthalmology services
• Intravitreal injections
• Retina diagnostics

Headquarters

HQ city

Edison

HQ country

United States

HQ region

North America

Offices20 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Medical and surgical retina care services billed to patients and/or insurance carriers. Revenue is generated through office visits, diagnostic procedures, intravitreal injections, laser treatments, and vitreoretinal surgeries. Most patients are referred by other providers or self-refer; insurance plans are accepted including Medicare and Medicare Advantage.
2. Continuous Care Program (Lumata Health): Partnership with Lumata Health to provide dedicated care coaching between office visits for chronic eye condition patients, typically at no cost for Medicare patients with supplemental coverage. Supports patient retention and adherence to treatment plans.
3. Clinical Trial Participation: Patients enrolled in clinical trials receive study-related eye exams at no cost; insurance is not required for trial-related procedures. Modest stipends may be provided to offset time and travel. Contributes to revenue while advancing treatment options.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

NJRetina is a private ophthalmology and vitreoretinal surgery practice that diagnoses and treats retinal diseases through office-based diagnostic evaluations, intravitreal injection therapies, and outpatient surgical procedures. The practice operates 20 office locations across New Jersey staffed by 33+ board-certified vitreoretinal specialists, and supplements clinical care with a clinical trials program and a care-coaching partnership (Lumata Health Continuous Care Program).

Product overview

NJRetina is a medical practice specializing in ophthalmology and vitreoretinal surgery, offering a comprehensive range of retinal disease treatments and surgical procedures. The practice operates as a multi-location network across New Jersey, providing diagnostic examination services (including fundus photography, fluorescein angiography, OCT, and visual field testing) alongside surgical treatments. Core surgical offerings include vitrectomy, scleral buckling, pneumatic retinopexy, and laser procedures (photocoagulation, retinopexy, photodynamic therapy). The practice also provides intravitreal injections for macular degeneration and diabetic retinopathy, cryotherapy, and a clinical fellowship training program. Patient support is enhanced through the Continuous Care Program with Lumata Health Care Coaches.

Differentiator

Problem solved

Functional benefit

Brands

• Continuous Care Program: A patient support program in partnership with Lumata Health providing dedicated care coaches to help patients manage chronic eye conditions.

Products and services

• Vitrectomy
• Laser Photocoagulation
• Laser Retinopexy
• Intravitreal Injection
• Cryotherapy
• Pneumatic Retinopexy
• Scleral Buckling Surgery
• Photodynamic Therapy (PDT)
• Diagnostic Retinal Examination
• Retina Fellowship Program
• Continuous Care Program

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Lumata HealthcoreStrategic or Co-development PartnerNJRetina has partnered with Lumata Health to offer the Continuous Care Program, providing patients with dedicated Care Coaches who work with their doctor to support eye care journeys. Care Coaches help patients understand doctor instructions, find low-cost prescriptions and vitamins, arrange transportation to appointments, and manage paperwork. The program is typically at no cost to Medicare patients with supplemental coverage.
• PRISM Vision GroupcoreStrategic or Co-development PartnerNJRetina is an affiliate of PRISM Vision Group, a larger eye care organization. PRISM Vision Group's President and CEO (Dr. Steven Madreperla) oversees NJRetina, and the group provides centralized resources including privacy notices, medical records authorization forms, careers pages, and administrative infrastructure.
• Rutgers Medical School / Robert Wood Johnson University HospitalcoreStrategic or Co-development PartnerNJRetina's 2-year vitreoretinal fellowship program is conducted in collaboration with Rutgers Medical School Robert Wood Johnson University Hospital. The fellowship is accredited by the Association of University Professors of Ophthalmology (AUPO). One fellow is selected every two years.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mid Atlantic Retina: Largest retina specialty group in the Mid-Atlantic region with multiple locations across Pennsylvania, New Jersey, Delaware, and Maryland. Directly comparable in subspecialty focus (vitreoretinal care), referral-driven GTM, and clinical trial participation.
• Retina Group of Washington: Large multi-location retina specialty practice in the DC/Mid-Atlantic region, providing vitreoretinal surgery, intravitreal injections, and clinical trial access. Comparable in scale, sub-specialization, and academic/clinical trial orientation.
• Vitreoretinal Consultants: Long-established retina specialty group in the New York metro with subspecialty-trained vitreoretinal surgeons offering medical and surgical retinal care. Directly comparable subspecialty practice model in the tri-state region.
• Retina Associates: Multi-physician retina specialty practice (locations in NJ, NY, PA) offering vitreoretinal medical and surgical care. Comparable in subspecialty depth, payer mix, and geographic proximity to NJRetina's core market.

Others

• PRISM Vision Group: Parent organization and management services platform supporting NJRetina and other affiliated ophthalmology practices. Directly comparable in the eye-care provider/ASC space; included because it sets the strategic, capital, and operational context for NJRetina.
• Regeneron Pharmaceuticals: Maker of EYLEA (aflibercept), the dominant anti-VEGF therapy that drives a large share of NJRetina's injection volume. Comparable ecosystem relevance: Regeneron's commercial success and pipeline directly shapes the demand, reimbursement, and clinical landscape in which NJRetina operates.
• Genentech (Roche): Maker of LUCENTIS (ranibizumab) and SUSVIMO, key anti-VEGF/retinal therapies that NJRetina administers. Comparable as a strategic pharmaceutical partner whose pipeline and pricing decisions materially affect NJRetina's procedure economics and treatment mix.
• Apellis Pharmaceuticals: Maker of SYFOVRE (pegcetacoplan), the first FDA-approved treatment for geographic atrophy, a condition NJRetina's physicians (notably Dr. Howard Fine) have pioneered in treating. Comparable as a pharmaceutical partner whose drug directly anchors NJRetina's dry-AMD treatment line.

Broad incumbents

• Wills Eye Hospital: Premier academic ophthalmology hospital in Philadelphia with a top-ranked retina service providing surgical, medical, and clinical trial-based retinal care. Comparable in retina specialty capability and clinical trial participation, though broader in scope as a full-service eye hospital.
• Massachusetts Eye and Ear (Mass Eye and Ear): Harvard-affiliated academic specialty hospital with a leading retina service providing advanced vitreoretinal care and clinical trials. Comparable in cutting-edge retinal treatments and research orientation; operates as a broader academic medical center rather than a community retina practice.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/nj.retina

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NJRetina